Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigious | ||
Readability |
H.S. sophomore Avg
|
New words:
baseline, compound, concentration, customary, degenerative, dosage, DSMB, EMEA, hour, IIb, infusion, parallel, suggest, unanimously
Removed:
efficient, enroll, Investigational, outgrowth, subsequently
Filing tables
Filing exhibits
- 10-Q Quarterly report
- 10.1 EX-10.1 Second Amended and Restated Convertible Promissory Note Purchase Agreement, by and Among the Company and the Purchasers Listed Therein, Dated August 13, 2007
- 31.1 EX-31.1 Certification of the Chief Executive Officer Pursuant to Rule 13(A) - 14(A)/RULE 15(D) - 14(A) of the Securities Exchange Act of 1934, As Amended
- 31.2 EX-31.2 Certification of the Chief Financial Officer Pursuant to Rule 13(A) - 14(A)/RULE 15(D) - 14(A) of the Securities Exchange Act of 1934, As Amended
- 32.1 EX-32.1 Certification of the Chief Executive Officer Pursuant to 18 U.s.c. Section 1350, As Adopted Pursuant to Section 906 of the Sarbanes-oxley Act of 2002
- 32.2 EX-32.2 Certification of the Chief Financial Officer Pursuant to 18 U.s.c. Section 1350, As Adopted Pursuant to Section 906 of the Sarbanes-oxley Act of 2002
Related press release
Alseres Pharmaceuticals similar filings
Filing view
External links